First confirm what is being treated
Alopecia areata is an immune-mediated condition that can cause patchy hair loss on the scalp or other hair-bearing areas. But not every bald patch is alopecia areata. Fungal infection, traction, scarring conditions, and other causes can also produce localized loss. Before discussing treatment, a dermatologist may examine the scalp and nails, use a dermatoscope, ask about personal and family history, and sometimes order selected tests or a biopsy. Testing depends on the findings; there is no single panel that every person needs. Read the AAD source record
This distinction matters because a cosmetic serum or shampoo cannot treat an autoimmune condition, infection, or scarring alopecia. If the patch is painful, inflamed, scaly, shiny, or rapidly expanding, arrange an assessment rather than trying several products first. An accurate diagnosis sets the right decision path.
Alopecia areata can also affect the nails. Small pits, a rough sandpaper-like surface or brittle nails are changes worth mentioning alongside patchy hair loss. They add to the history; similar nail changes can have other causes, so the clinician considers them with the hair and scalp examination. Photograph a new change and note when it began. The AAD description of hair and nail signs shows why this detail can matter. For a patch whose cause is still unclear, start with the patchy hair-loss assessment guide.
Treatment depends on extent and course
There is no one treatment that works for everyone, and treatment is not always recommended. AAD patient guidance describes that one or two recent patches may be monitored because some people, particularly children, regrow hair without treatment. A dermatologist weighs extent, duration, location, age, and the person’s preferences. A watch-and-review plan is still a plan: ask what changes should prompt an earlier follow-up and when the decision will be revisited.
For a small number of patches in adults, a dermatologist may discuss corticosteroid injections into affected areas or a topical corticosteroid. These are clinician-directed options, with different burdens and possible effects. A topical medicine used on one area is not interchangeable with an injection, and neither should be copied from someone else’s treatment plan. Minoxidil may sometimes be used to help maintain regrowth after other treatment, but it does not turn a cosmetic serum into an alopecia areata therapy. The choice and instructions should come from the clinician who confirms the diagnosis.
More extensive loss can call for a different conversation. Dermatologists may discuss contact immunotherapy or systemic medicines, including JAK inhibitors, with suitable patients. These treatments are not equivalent to over-the-counter hair products; they have specific eligibility, monitoring, and safety considerations. In the United States, the current FDA label identifies baricitinib as a treatment option for adults with severe alopecia areata. Its prescribing information includes serious warnings and calls for clinical evaluation and monitoring. That label detail is one example of why decisions belong with a qualified prescriber, not a consumer dose guide. Read the FDA label source record
| Situation after diagnosis | Discussion to have with the dermatologist |
|---|---|
| One or a few recent patches | Whether observation or local treatment is reasonable, and what changes merit review |
| Patches that persist or spread | Whether a different local approach, further evaluation, or a revised plan is appropriate |
| Extensive scalp or body-hair loss | Whether a systemic or specialist treatment should be considered and what screening or monitoring it involves |
| Eyebrow, eyelash, or nail changes | Whether these affect assessment, treatment goals, or eye protection and daily comfort |
| Treatment side effects or burden | Whether the benefit-risk balance still fits your priorities and health circumstances |
Questions to take to the visit
Ask the clinician to explain what supports the diagnosis and what alternatives were considered. Then make the treatment conversation specific:
- How much of the scalp or other hair-bearing areas is involved?
- Is the condition active, stable, or changing, and how will we tell?
- Is observation appropriate for now, and what is the follow-up point?
- What are the realistic goals of the proposed treatment: slowing loss, regrowth, maintenance, or another outcome?
- Which possible side effects, screening tests, or monitoring apply to this option?
- How might treatment affect my existing medicines, other health conditions, pregnancy plans, or daily routine?
- What should I do if the patches spread or a treatment causes a problem?
The aim is not to demand a particular medicine. It is to understand why an option fits your situation and what trade-offs come with it. Bring a list of current medicines and supplements, any prior treatments, and a few dated photographs if available. Include eyebrow, eyelash, or nail changes if you have noticed them; clinicians may consider those details during an assessment.
For systemic options, ask who will coordinate monitoring and whom to contact if you develop a new symptom. The FDA label contains details that cannot be reduced to a short hair article, including warnings and clinical evaluations. A prescriber can explain which apply to you and how they affect the decision. Do not start, stop, or change a prescription based on this overview.
Understand what a study result can and cannot promise
Clinical studies usually focus on defined groups, disease severity, treatment duration, and a specific outcome. A result in people with extensive disease cannot automatically predict what will happen in a person with one small patch. Likewise, a study result does not promise an individual response or mean that a particular medicine is suitable for everyone.
The FDA label for a prescription medicine is useful for its approved use and safety information, but it is not a personalized recommendation. Read it with the prescriber who can consider other conditions, medicines, and monitoring needs. Do not change or start a medicine based on a headline, online discussion, or another person’s before-and-after images.
Progress can also be uneven. Some people regrow hair without treatment, some respond to treatment, and some experience recurrent or persistent patches. Ask how the clinician will assess response and when they would reconsider the plan. A written review point can help avoid switching treatments after every short-term fluctuation.
Separate medical treatment from appearance support
Treatment can take time, and it is reasonable to want practical help while you decide or wait. Wigs, hairpieces, concealers, eyebrow products, and styling choices may help with appearance or comfort. They do not alter the underlying immune condition or establish that regrowth is occurring. If scalp skin is sensitive, ask the clinician how to avoid irritation from adhesives, cosmetics, or friction.
General cleansing and gentle handling can support comfort, but they are not treatments for alopecia areata. If you use a cosmetic product, check its directions and stop if it irritates the scalp. Folivis Hair Growth Serum is a leave-in cosmetic scalp-care product; product facts are not evidence that it treats alopecia areata. Folivis Hair Growth Supplement is not a substitute for diagnosis or prescribed care. See Folivis product facts
When to seek a review sooner
Contact your clinician if loss spreads quickly, new areas appear, the scalp becomes painful or inflamed, or treatment causes a concerning effect. If eyelashes are affected, ask about eye protection and whether the treatment plan should change. If a prescribed systemic treatment is being considered, discuss the current label and monitoring requirements with the prescriber; do not rely on a general web article to manage it.
Alopecia areata can be emotionally difficult. Tell the clinician if the change affects your confidence, work, school, or social life. Appearance support and emotional support can be part of care even when they do not treat the cause.
The next step is a diagnosis-led conversation. Find out whether the patch is alopecia areata, how extensive it is, and whether observation or treatment best fits your circumstances. Then agree on the goal, safety checks, and a review point. That is more useful than treating every patch with the same product or expecting one option to work for everyone.